Financials data is unavailable for this security.
View more
Year on year Calliditas Therapeutics AB had net income fall 13.08% from a loss of 412.27m to a larger loss of 466.19m despite a 50.32% increase in revenues from 802.88m to 1.21bn. An increase in the cost of goods sold as a percentage of sales from 1.89% to 5.01% was a component in the falling net income despite rising revenues.
Gross margin | 93.46% |
---|---|
Net profit margin | -30.00% |
Operating margin | -22.05% |
Return on assets | -27.80% |
---|---|
Return on equity | -157.20% |
Return on investment | -35.11% |
More ▼
Cash flow in SEKView more
In 2023, cash reserves at Calliditas Therapeutics AB fell by 275.36m. Cash Flow from Financing totalled 199.65m or 16.54% of revenues. In addition the company used 434.66m for operations while cash used for investing totalled 13.75m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.98 |
---|---|
Tangible book value per share | -6.76 |
More ▼
Balance sheet in SEKView more
Current ratio | 2.69 |
---|---|
Quick ratio | 2.59 |
Total debt/total equity | 9.44 |
---|---|
Total debt/total capital | 0.9042 |
More ▼